One Rare Disease Drug’s Access Journey Across The Globe
Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.
You may also be interested in...
Now that the EMA has followed its US counterpart in granting approval for its cystic fibrosis drug Symkevi, Vertex will once again have to navigate Europe's various reimbursement systems, with observers keeping a close eye on how talks with NICE go.
Vertex’s portfolio-based access deal in Denmark will give patients quicker access to a range of cystic fibrosis drugs and give budget predictability to the company and government.
Orkambi is the first combo drug to be priced lower than solo therapy with one of its components, but it stands to increase Vertex’s patient base exponentially.